Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171405 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
A Phase 3 study of Hypertension, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 10
- Study locations
NCT00171405 is a Phase 3 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 250 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 2 states.
The verdict
NCT00171405, a Phase 3 study of Hypertension, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.
Conditions Studied
Interventions
- DRUG aliskiren
Study Locations (10)
Other
- Investigative Site - Deurne
- Investigative Site - Ste-Fov
- Investigative Site - Krassel
- Investigative Site - Broni
- Investigative Site - Rotterdam
- Investigative Site - Lima
- Investigative Site - Moscow
- Investigative Site - Basel
- Investigative Site - London
New Jersey
- Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171405
The ClinicalTrials.gov registry entry for NCT00171405 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which aliskiren is the first listed.
NCT00171405 reports 10 study locations spanning 2 distinct geographic areas - top geographies include Other, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00171405 about?
NCT00171405 is a clinical study titled "A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg". The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.
What is the current status of trial NCT00171405?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2005-06. Estimated completion is 2006-02.
What conditions does trial NCT00171405 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00171405?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00171405?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171405 being conducted?
This trial has 10 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.